BGH ruling could reshape how online platforms market medical cannabis treatments
The Federal Court of Justice (Bundesgerichtshof, BGH) in Karlsruhe is hearing arguments today that could fundamentally alter the medical cannabis landscape in Germany. At stake: whether online platforms can legally advertise medical cannabis treatments, or if such marketing violates the country’s strict Heilmittelwerbegesetz (Therapeutic Products Advertising Act).
The case, brought by the German Competition Center (Wettbewerbszentrale), targets internet portals that connect patients with doctors prescribing medical cannabis. These platforms have flourished in a regulatory grey zone created by Germany’s partial cannabis legalization, which permits recreational use under certain conditions while keeping medical cannabis prescription-only.
The Legal Grey Zone
The challenge facing the court centers on a fundamental contradiction in current cannabis policy. While adult-use cannabis has been partially legalized, medical cannabis remains under strict pharmaceutical regulations that prohibit misleading advertising for medications and medical treatments. Online platforms have capitalized on this ambiguity by positioning themselves as patient-doctor matchmaking services rather than direct advertisers of medical treatments.
As German media outlet taz reports, “online pharmacies are the big winners” of this unclear legal situation. The business model has proven lucrative: connect patients seeking medical cannabis with doctors willing to prescribe it, all while operating in what may or may not constitute illegal medical advertising.
What’s at Stake
Today’s hearing could determine whether these digital-first business models can continue operating or whether Germany’s strict advertising regulations will force a fundamental restructuring of how medical cannabis reaches patients.
The Heilmittelwerbegesetz was designed to protect consumers from misleading medical claims, but its application to cannabis—a substance now straddling both recreational and medical categories—remains legally untested at the federal level.
For cannabis startups and telehealth platforms operating in Germany, the BGH’s eventual ruling could either validate their current approach or require immediate pivots in their marketing strategies and business models.
Industry Impact
The decision will likely reverberate beyond Germany’s borders, as other European markets watching Germany’s cannabis experiment closely. A ruling against online medical cannabis advertising could cool investor enthusiasm for telehealth-focused cannabis ventures, while a favorable decision might accelerate the digitalization of medical cannabis access across the EU.
We’ll be monitoring the case closely and will update our readers as the BGH issues its ruling.
